Fast Track Initiative, Inc.
VC Fund
Hongo, Japan
Fast Track Initiative, Inc. is a VC fund in Hongo focused on Health Care and Biotechnology. Fast Track Initiative is a venture capital firm with an exclusive focus on life sciences and healthcare services.
- Total investments:
- 83
- Last investment:
- Lead investor:
- 28%
- Fund size:
- $1.1B
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Fast Track Initiative, Inc. invests in
Stages Fast Track Initiative, Inc. invests in
Countries Fast Track Initiative, Inc. invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $345k–$117M
- Series A
- $3M–$113M
- Series B
- $9.5M–$91M
Investment Focus
Industry
- Health Care 21 (25%)
- Biotechnology 19 (23%)
- Medical 14 (17%)
- Medical Device 6 (7%)
- Therapeutics 5 (6%)
Stage
- Series A 20 (24%)
- Series B 15 (18%)
- Seed 14 (17%)
- Funding Round 11 (13%)
- Series C 4 (5%)
Country
- Japan 38 (46%)
- United States 3 (4%)
- United Kingdom 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Hiroko Kimura
Principal
|
Principal | Total investments: 0 | Find email | |
Hiroko Kimura
Principal
|
Principal | Total investments: 2 | Find email | |
Keita Kiriya
Analyst
|
Analyst | Total investments: 0 | Find email | |
Koji Yasuda
Life science venture capitalist
|
Life science venture capitalist | Total investments: 3 | Find email | |
Koki Fukatsu
Associate
|
Associate | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Neusignal Therapeutics
|
Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses. | $32.8M / Series B / Jun 30, 2026 | |
NovAccel
|
NovAccel operates as a deep tech company, ensure a stable supply of medical radioisotopes. | $7.6M / Seed / May 10, 2026 | |
Storm Therapeutics
|
Targeting pathways that modify RNA to deliver novel cancer therapeutics. | $56M / Series C / Apr 16, 2026 | |
|
SONIRE Therapeutics
|
SONIRE Therapeutics is a clinical-stage medical device company. It is a U.S. subsidiary of SONIRE Therapeutics Co., Ltd.. | $18M / Series A / Apr 15, 2026 | |
Sonire Therapeutics
|
SONIRE Therapeutics Inc. (SONIRE) is working on a next-generation high-intensity focused ultrasound (HIFU) therapy system that will employ acoustic engineering (ultrasound) technologies developed through cutting-edge academic research. SONIRE has been working on a next-generation high-intensity focused ultrasound (HIFU) treatment system as a noveltherapeutic modality with the goal of giving cancer patients and their families a new future. | $18M / Series A / Apr 15, 2026 | |
Quali
|
Quali is dedicated to developing innovative products and solutions that support microsurgery, with the goal of addressing critical challenges in the medical field and improving patient outcomes and overall quality of life. | $11.5M / Series A / Feb 06, 2026 | |
|
Sonire Therapeutics
|
SONIRE Therapeutics Inc. (SONIRE) is working on a next-generation high-intensity focused ultrasound (HIFU) therapy system that will employ acoustic engineering (ultrasound) technologies developed through cutting-edge academic research. SONIRE has been working on a next-generation high-intensity focused ultrasound (HIFU) treatment system as a noveltherapeutic modality with the goal of giving cancer patients and their families a new future. | $8M / Series C / Jan 23, 2026 | |
Ichirou
|
Ichirou provides digital senior care support services to connect elderly people with caretakers. It offers caretaker services for different types of support, including housework, hospital care, nursing, hospital and doctor visits, and shopping assistance. | $7.7M / Series B / Sep 11, 2025 | |
Metagen Therapeutics
|
Metagen Therapeutics (MGTx) is a clinical-stage company operating Japan’s first GMP-compliant manufacturing platform for fecal microbiota transplantation (FMT) therapies. The company combines proprietary paired metagenomic datasets with AI/ML-driven donor-recipient matching to advance precision microbiome medicine across ulcerative colitis,immuno-oncology, and neurodegenerative disease. Headquartered in Tsuruoka, Japan, MGTx leverages a cross-border regulatory strategy spanning PMDA and FDA pathways, positioning it as a platform bridging Japanese clinical innovation with global market access. | $15.7M / Series B / Sep 08, 2025 | |
|
Metagen Therapeutics
|
Metagen Therapeutics (MGTx) is a clinical-stage company operating Japan’s first GMP-compliant manufacturing platform for fecal microbiota transplantation (FMT) therapies. The company combines proprietary paired metagenomic datasets with AI/ML-driven donor-recipient matching to advance precision microbiome medicine across ulcerative colitis,immuno-oncology, and neurodegenerative disease. Headquartered in Tsuruoka, Japan, MGTx leverages a cross-border regulatory strategy spanning PMDA and FDA pathways, positioning it as a platform bridging Japanese clinical innovation with global market access. | $15.7M / Series B / Sep 08, 2025 | |
| See all 83 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Fast Track Initiative, Inc. invest in?
Fast Track Initiative, Inc. invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 83 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Fast Track Initiative, Inc.'s check size?
Fast Track Initiative, Inc. typically joins rounds of $345k–$117M at Seed, $3M–$113M at Series A and $9.5M–$91M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Fast Track Initiative, Inc. participates in.
How do I contact Fast Track Initiative, Inc.?
Public channels for Fast Track Initiative, Inc. include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Fast Track Initiative, Inc.?
The team at Fast Track Initiative, Inc. includes Hiroko Kimura (Principal), Hiroko Kimura (Principal) and Keita Kiriya (Analyst), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
